JP7602481B2 - 肉腫を治療する方法に有用な組み合わせ - Google Patents

肉腫を治療する方法に有用な組み合わせ Download PDF

Info

Publication number
JP7602481B2
JP7602481B2 JP2021557396A JP2021557396A JP7602481B2 JP 7602481 B2 JP7602481 B2 JP 7602481B2 JP 2021557396 A JP2021557396 A JP 2021557396A JP 2021557396 A JP2021557396 A JP 2021557396A JP 7602481 B2 JP7602481 B2 JP 7602481B2
Authority
JP
Japan
Prior art keywords
compound
subject
sarcoma
pharmaceutical composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519930A5 (enExample
JP2022519930A (ja
Inventor
マーラ エル ウィートール
リャンシャン ツァオ
ジョセフィン シーディ
ロバート シュピーゲル
Original Assignee
ピーティーシー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス， インコーポレイテッド filed Critical ピーティーシー セラピューティクス， インコーポレイテッド
Publication of JP2022519930A publication Critical patent/JP2022519930A/ja
Publication of JP2022519930A5 publication Critical patent/JP2022519930A5/ja
Application granted granted Critical
Publication of JP7602481B2 publication Critical patent/JP7602481B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021557396A 2019-03-27 2020-03-27 肉腫を治療する方法に有用な組み合わせ Active JP7602481B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
US62/825,017 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (3)

Publication Number Publication Date
JP2022519930A JP2022519930A (ja) 2022-03-25
JP2022519930A5 JP2022519930A5 (enExample) 2023-04-04
JP7602481B2 true JP7602481B2 (ja) 2024-12-18

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557396A Active JP7602481B2 (ja) 2019-03-27 2020-03-27 肉腫を治療する方法に有用な組み合わせ

Country Status (11)

Country Link
US (1) US20220152024A1 (enExample)
EP (1) EP3947379A4 (enExample)
JP (1) JP7602481B2 (enExample)
CN (1) CN114096537B (enExample)
AU (1) AU2020248103A1 (enExample)
BR (1) BR112021019170A2 (enExample)
CA (1) CA3134648A1 (enExample)
EA (1) EA202192349A1 (enExample)
IL (1) IL286647A (enExample)
MX (1) MX2021011688A (enExample)
WO (1) WO2020198705A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504290A (ja) 2012-11-21 2016-02-12 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
KR20090094148A (ko) * 2006-12-20 2009-09-03 제이-씨 헬쓰 케어 리미티드 페길화 리포좀 독소루비신의 투여 방법
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504290A (ja) 2012-11-21 2016-02-12 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤

Also Published As

Publication number Publication date
CA3134648A1 (en) 2020-10-01
EP3947379A4 (en) 2022-12-21
CN114096537B (zh) 2025-01-10
BR112021019170A2 (pt) 2022-03-03
CN114096537A (zh) 2022-02-25
EP3947379A1 (en) 2022-02-09
JP2022519930A (ja) 2022-03-25
IL286647A (en) 2021-10-31
WO2020198705A1 (en) 2020-10-01
MX2021011688A (es) 2022-01-24
AU2020248103A1 (en) 2021-10-21
EA202192349A1 (ru) 2022-02-01
US20220152024A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
US11458126B2 (en) DHODH inhibitor for use in treating hematologic cancers
DK2544680T3 (en) USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
JP2025032069A (ja) 膵臓癌を治療する方法
JP2022506829A (ja) エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
TWI719765B (zh) 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
US20220152024A1 (en) Combinations useful in a method for treating sarcoma
JP7428717B2 (ja) 急性骨髄性白血病の治療方法
EA046841B1 (ru) Комбинации, пригодные в способе лечения саркомы
JP7822619B2 (ja) 胆管癌の処置のためのパノビノスタットを含む併用療法
US20220143016A1 (en) Method for treating a multiple myeloma
EA047152B1 (ru) Способ лечения множественной миеломы
TW202220654A (zh) 用於治療癌症之組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241206

R150 Certificate of patent or registration of utility model

Ref document number: 7602481

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150